), a company dedicated to revenue cycle management and supply
chain management, recently revealed that the Cancer Treatment
Centers of America (CTCA) had appointed it to derive lower costs
for new projects under construction across its nation-wide chain
of hospitals. This fresh understanding to utilize MedAssets
Capital and Construction Solutions builds upon the existing
arrangements between the two sides in such areas as Reimbursement
and Charge Integrity.
MedAssets furnishes a tech-friendly offering that provides a
mechanism for comparison and purchase of construction-related
products. Furthermore, by centralizing purchase decisions, and
utilizing both analysis and intelligence in its decision making,
MedAssets intends to deliver both financial and operational
benefits to CTCA. In other words, MedAssets' clients benefit
across a range of parameters, including cost savings.
Every cancer hospital of CTCA makes use of up-to-date
technology and trained staff. Due to the rising demand for new
services, CTCA needs to add new facilities at its hospitals. By
appointing MedAssets, CTCA benefits from a cloud-based offering
that allows financial control of projects from start to
Cancer Treatment Centers of America (CTCA) is a chain of
hospitals that provide care for cancer patients. Through programs
such as Patient Empowerment Medicine, it disseminates data about
cancer such that cancer victims may take control over their
MedAssets teams with health-related entities to implement
revenue cycle management and other offerings that curb costs and
lead to better margins and cash flow. The company works with over
4,200 hospitals and 122,000 health providers.
We currently have a Zacks Rank #3 (Hold) on MedAssets. We are
more positive about
Air Methods Corp.
Express Scripts Holding Company
) each of which carry a Zacks Rank #2 (Buy) and are expected to
AIR METHODS CRP (AIRM): Free Stock Analysis
EXPRESS SCRIPTS (ESRX): Free Stock Analysis
HEALTHWAYS INC (HWAY): Free Stock Analysis
MEDASSETS INC (MDAS): Free Stock Analysis
To read this article on Zacks.com click here.